UK Equity Income

Investors are struggling to find ways to beat inflation in the UK, with savings accounts paying virtually nothing and bond yields squeezed by demand, but there are a number of funds out there which can deliver for investors.

After a decade of scant gains, some investors are now piling into pharmaceuticals as a combination of high yields and attractive valuations draw managers in, but is this the start of a decade-long move up?

BlackRock's Nick McLeod-Clark has stepped down from running the firm's £698m UK Income fund to take an extended period of leave to recover from poor health.

Superficially attractive equity market valuations are concealing a number of warning signs for investors, according to RWC Partners' income managers Nick Purves and Ian Lance.

Vodafone shares have jumped to the top of the FTSE 100 leaderboard on talk that US peers Verizon and AT&T are working on a $245bn break-up bid for the firm.

UK income investors could be in for a dividend windfall as sterling continues to slide against the dollar, analysts have suggested.

Troy's Trojan Income fund manager Francis Brooke has sold his position in Aberdeen Asset Management after its share price doubled in the space of 12 months.

In a low-rate world, the feverish scramble for yield means the equity income story has been well-flagged to investors in recent years, but are key shares now reaching an unsustainable peak?

Standard Life Investments' Thomas Moore, manager of the £105m UK Equity Income Unconstrained fund, has sold out of UK pharmaceuticals amid fears the sector faces further earnings downgrades this year.

Troy Asset Management is to soft-close Francis Brooke's Trojan Income fund in order to protect performance for existing investors.